Navigation Links
Supelco(R) Expands Ascentis(R) Express HPLC Columns Line for High-Speed and High-Efficiency Separations
Date:9/3/2008

Ascentis Express RP-Amide provides improved selectivity for polar compounds

ST. LOUIS, Sept. 3 /PRNewswire-FirstCall/ -- Supelco, a division of Sigma-Aldrich (Nasdaq: SIAL), has expanded the Ascentis Express product line (http://www.sigma-aldrich.com/express), a family of innovative HPLC columns designed to provide the analysis speed and resolving power of sub-2-micron columns with a 50% reduction in backpressure. Ascentis Express RP-Amide, an embedded polar group chemistry, provides an alternate selectivity to the conventional C18 and C8 phases.

"The combination of the RP-Amide advanced bonding chemistry and the Fused-Core(TM) particle provides a polar column for high-speed and high-resolution separations," said Wayne K. Way, Marketing Manager at Supelco in Bellefonte, PA. "The Ascentis Express RP-Amide provides improved peak shape for basic compounds."

The key technology in the Ascentis Express column is the Fused-Core particle. These high-purity silica particles measure 2.7 microns overall, with a 0.5 micron-thick porous shell. Relative to columns using conventional sub-2-micron particles, Ascentis Express columns generate comparable efficiencies but with half the backpressure.

Supelco's offering of HPLC products is one part of Sigma-Aldrich's technological and value-driven products that, combined with our services and support, provide complete analytical applications solutions.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.

*Fused-Core is a trademark of Advanced Materials Technology. Sigma-Aldrich, Supelco and Ascentis are registered trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Supelco(R) Introduces Ascentis(R) Express HILIC HPLC Columns for High-Speed and High-Efficiency Separations
2. ATS Medical Expands Open Pivot Heart Valve Offerings
3. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
4. BioLife Solutions Expands Scientific Advisory Board
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
7. Pharsight Expands Strategic Consulting Services Team
8. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
9. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
10. AQUISS Expands Into Significant New Territory
11. NanoBio Expands Drug Development Team for Its Anti-Infective Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
Breaking Biology Technology:
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
Breaking Biology News(10 mins):